BioSpace News Archive

Telix Pharmaceuticals Limited announces the initiation of two new investigator-led studies to evaluate the potential utility of the Company’s late-stage imaging portfolio in women’s health, initially in two sub-types of breast cancer with a significant unmet medical need.

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“Lixte”), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, noted that in pre-clinical studies its lead clinical compound, LB-100, a protein phosphatase 2A (PP2A) inhibitor, was reported to reduce behavioral sensitization underlying addiction to methamphetamine (METH).

Data published in ClinicoEconomics and Outcomes Research show that the novel i-FACTOR is not only cost-effective compared to autograft in ACDF surgery but is the dominant economic strategy.

A cardiac assist device is a mechanical pump that’s used to support heart function and blood flow in people who have weakened hearts.

Day by day openness to ecological contamination and ascend in populace helpless to indoor air toxins drive the development of the worldwide asthma demonstrative and checking gadget area.

Medical clinic cost saving because of Healthcare chatbots, ascend in Internet availability and brilliant gadget application, and flood in quiet holding up time drive the development of the worldwide Healthcare chatbot market

Rise in incidence of malaria, increase in healthcare expenditure among people, and surge in adoption of malaria diagnostics tools across the world fuel the growth of the global malaria diagnostics market.

Over the last 40 years, HIV has shifted from a deadly and mysterious virus to one that can be controlled with daily drugs. But attempts to completely eliminate the virus from the bodies of people living with HIV, curing them for good, have failed.

Cue Biopharma, Inc. provided a business and clinical progress update for the second quarter 2021.

Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced a more detailed summary of the national study results announced by the Company on July 13, 2021,